Loading...
•
Dec 31, 2021
PMV Pharma Q4 2021 Earnings Report
PMV Pharma's financial results for Q4 2021 were reported, highlighting the progress of PC14586 and the expansion of the pipeline.
Key Takeaways
PMV Pharma reported its Q4 and full year 2021 financial results, with a focus on the continued development of PC14586 and the expansion of its pipeline. The company ended the year with a strong cash position of $314.1 million.
Continued progress with Phase 1/2 study of PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation.
Advanced WIP1 inhibitor program into lead optimization.
Binh Vu Ph.D. promoted to Senior Vice President, Discovery Research and CMC and Melissa Dumble Ph.D. to Senior Vice President, Preclinical Development and Translational Science.
Kirsten Flowers appointed to the Board of Directors.
PMV Pharma
PMV Pharma
Forward Guidance
PMV Pharma anticipates a productive 2022, focusing on the development of PC14586 and advancing its discovery pipeline.
Positive Outlook
- Steady progress in the development of PC14586.
- Initial data from ongoing Phase 1/2 trial expected in the first half of 2022.
- Strong leadership.
- Solid balance sheet.
- Advancement of discovery pipeline of small molecule, tumor-agnostic precision medicine products.
Challenges Ahead
- Success of product candidate development activities and planned clinical trials are subject to risk.
- Company's ability to execute on its strategy and operate as an early clinical stage company is subject to risk.
- Potential for clinical trials of PC14586 or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results.
- Company's ability to fund operations are subject to risk.
- Impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations.